TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Tyra Bioscience ( (TYRA) ) has issued an announcement.
On June 30, 2025, Tyra Biosciences announced the commencement of the SURF302 Phase 2 clinical study for TYRA-300, targeting low-grade, intermediate risk non-muscle invasive bladder cancer. This study, which will enroll up to 90 participants primarily in the U.S., aims to evaluate the efficacy and safety of TYRA-300, with initial results expected in the first half of 2026. Additionally, TYRA-300 is being tested for pediatric achondroplasia in the BEACH301 Phase 2 study, with first child dosing anticipated in the latter half of 2025.
The most recent analyst rating on (TYRA) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Tyra Bioscience stock, see the TYRA Stock Forecast page.
Spark’s Take on TYRA Stock
According to Spark, TipRanks’ AI Analyst, TYRA is a Neutral.
Tyra Bioscience’s overall stock score reflects its high-risk profile typical for early-stage biotechnology firms. While the company demonstrates strong liquidity, its lack of revenue and increasing operational losses highlight financial challenges. Technical indicators show positive momentum, but the high valuation risk due to negative earnings limits the score. Investors should be cautious, considering both the potential for significant growth and the inherent risks.
To see Spark’s full report on TYRA stock, click here.
More about Tyra Bioscience
Tyra Biosciences, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer and other serious diseases. The company is particularly engaged in creating targeted treatments for conditions with specific genetic alterations.
Average Trading Volume: 359,571
Technical Sentiment Signal: Sell
Current Market Cap: $483.9M
For detailed information about TYRA stock, go to TipRanks’ Stock Analysis page.